On September 3, 2024 NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, reported that Paul Y. Song, MD, Chairman and CEO of NKGen, will participate in a virtual presentation and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, on September 9-11, 2024 (Press release, NKMax America, SEP 3, 2024, https://nkgenbiotech.com/nkgen-biotech-to-present-at-the-h-c-wainwright-26th-annual-global-investment-conference/ [SID1234646302]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The virtual presentation will be available on-demand for registered participants through the H.C. Wainwright conference portal starting at 7:00 AM Eastern Time on Monday, September 9, 2024. Registered participants can submit their questions to NKGen after the presentation has become available. Dr. Song will also be available for virtual one-on-one investor meetings during the conference.
For more information about the conference and to register for a one-on-one meeting, please visit the conference website at View Source
A webcast of the pre-recorded presentation can be accessed under the Events and Presentations page in the Investors section of the Company’s website at www.nkgenbiotech.com. An archived replay of the webcast will be available for 90 days following the presentation.